MALVERN, Pa., Aug. 8, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceuticalcompany focused on developing novel therapeutics in immune-mediated diseases, announces today that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signalling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.
Realm Therapeutics plcAlex Martin, Chief Executive OfficerMarella Thorell, Chief Financial Officer and Chief Operating Officer Outside US: +44 (0) 20 3727 1000 US: +1 212 600 1902
Argot PartnersStephanie Marks / Claudia Styslinger+1 212 600 1902
FTI ConsultingSimon Conway / Mo Noonan+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer+44 (0) 20 7496 3000
View original content:http://www.prnewswire.com/news-releases/realm-therapeutics-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-300693471.html
SOURCE Realm Therapeutics
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All